# Avyia


## Posts

- [Can Ketamine Microdosing Ease Postpartum Depression and Reduce Substance Cravings?](https://avyia.com/can-ketamine-microdosing-ease-postpartum-depression-and-reduce-substance-cravings/): [vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”] Authors:  Jason Chang, DNP, ARNP-C Affiliations:  AVYIA [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]Corresponding Author/Contact:  jason.chang@avyia.com[/vc_column_text][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit”...
- [Can Ketamine IV Infusions Alleviate PTSD After Prolonged Grief? Mrs. Physicist Dreamer, a 64‑year‑old widow was able to do it.](https://avyia.com/can-ketamine-iv-infusions-alleviate-ptsd-after-prolonged-grief/): [vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”] Authors:  Jason Chang, DNP, ARNP-C Affiliations:  AVYIA [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]Corresponding Author/Contact:  jason.chang@avyia.com[/vc_column_text][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit”...
- [The Mechanisms Behind Ketamine's Rapid Antidepressant Effects: A Systematic Review on Molecular Neuroplasticity](https://avyia.com/ketamine-and-neuroplasticity-in-depression/): A 2022 systematic review published in Frontiers in Psychiatry explores the molecular underpinnings of ketamine’s rapid antidepressant effects, focusing on its role in promoting neuroplasticity. This paper compiles findings from animal models, human clinical data, and molecular biology to explain how ketamine achieves its fast-acting mood-lifting properties — often within hours — in contrast to traditional antidepressants that can take weeks. The review highlights that ketamine’s antidepressant efficacy stems not solely from its NMDA receptor antagonism, but from a complex cascade of downstream neuroadaptive processes, especially involving synaptogenesis and neural circuit modulation. Core Focus of the Review Article: The Mechanisms...
- [What to Know About Microdosing: Definition, Benefits, and Risks](https://avyia.com/microdosing-benefits-and-risks/): Microdosing refers to the practice of taking very small, sub-perceptual doses of psychedelic substances such as LSD, psilocybin (magic mushrooms), or other compounds like ketamine, with the aim of enhancing mood, focus, and mental clarity without inducing a full psychedelic experience. While this practice has gained popularity through anecdotal reports and cultural trends, particularly in creative and tech communities, scientific research on its efficacy and safety is still in early stages. This overview is based on the 2024 article from Medical News Today, which summarizes the current understanding of microdosing’s potential benefits and risks. What Is Microdosing? Microdosing involves consuming...
- [Oral Ketamine RCT in New Zealand: Significant Depression Relief with Manageable Side Effects](https://avyia.com/r-107-oral-ketamine-for-depression/): A recent randomized controlled trial (RCT) in New Zealand evaluating the R-107 oral ketamine formulation has shown significant effectiveness in reducing symptoms of depression, including in patients with treatment-resistant depression (TRD). Developed by Douglas Pharmaceuticals, R-107 represents a novel, patent-protected, slow-release ketamine tablet designed for outpatient use. While the trial demonstrated strong antidepressant efficacy, some side effects were noted, prompting further investigation into safety, dosing, and long-term usability. Study Overview Drug Candidate: R-107 (oral slow-release racemic ketamine) Location: New Zealand Developer: Douglas Pharmaceuticals Trial Type: Double-blind, randomized, placebo-controlled trial Primary Outcome: Reduction in depressive symptoms measured by standardized psychiatric scales...
- [UK Slow-Release Ketamine Tablet Trial Shows Reduced Relapse in Depression: Phase 2 Results](https://avyia.com/oral-ketamine-for-depression-relapse/): A UK-based Phase 2 clinical trial has found that a slow-release oral ketamine tablet significantly reduced the risk of relapse in patients with depression. The study, which enrolled 231 participants, reported that only 57% of those receiving ketamine relapsed after 13 weeks, compared to 71% in the placebo group. These findings mark a significant step toward more convenient and scalable delivery methods for ketamine-based antidepressant therapy. Study Overview Location: United Kingdom Study Type: Phase 2, randomized, placebo-controlled trial Sample Size: 231 patients with major depressive disorder (MDD) Intervention: Slow-release oral ketamine tablet Comparator: Placebo tablet (matched appearance and schedule) Follow-up...
- [KADS Trial Shows Rapid Suicidal Ideation Reduction with Ketamine: 88% Remission in 90 Minutes](https://avyia.com/ketamine-for-suicidal-ideation/): The Ketamine for Acute Depression and Suicidality (KADS) trial has emerged as a landmark study demonstrating the extraordinary speed and effectiveness of ketamine in reducing suicidal ideation (SI). One of the most striking findings reported from this trial is an 88% remission rate in suicidal thoughts within 90 minutes of subcutaneous ketamine administration — compared to only 33% in the placebo group. This dramatic difference underscores ketamine’s potential as a life-saving intervention in psychiatric emergencies and highlights its role in the rapidly evolving field of mood disorder therapeutics. KADS Trial Overview Study Name: Ketamine for Acute Depression and Suicidality (KADS) ...
- [Ketamine for Cancer and Chronic Pain Management: Insights from Frontiers in Pharmacology](https://avyia.com/ketamine-for-cancer-and-chronic-pain/): A 2020 review article published in Frontiers in Pharmacology (doi:10.3389/fphar.2020.599721) highlights the expanding role of ketamine in the treatment of cancer-related and chronic non-cancer pain. The authors examine a range of clinical and mechanistic evidence that supports ketamine’s use as an effective, multi-modal analgesic for patients with severe, refractory pain — especially when conventional opioids and adjuvants prove insufficient. As healthcare providers seek safer, more effective alternatives to long-term opioid therapy, ketamine offers a unique therapeutic profile, combining analgesic potency, rapid onset, NMDA receptor antagonism, and utility across various routes of administration. Overview of the Review Journal: Frontiers in Pharmacology,...
- [Ketamine vs. Ketorolac in Veterans: Both Reduce PTSD and Pain, Ketamine Well Tolerated](https://avyia.com/ketamine-vs-ketorolac-for-ptsd/): A 2019 randomized clinical trial published in Chronic Stress (PMC6549592) compared the effects of intravenous ketamine versus ketorolac in U.S. military veterans suffering from comorbid PTSD and chronic pain. The study found that both drugs significantly reduced PTSD symptoms and pain intensity, with ketamine demonstrating good tolerability and potential for rapid symptom relief. This trial adds to the growing body of evidence supporting ketamine’s role in trauma treatment — particularly for veterans with overlapping psychological and physical burdens — while also emphasizing the importance of integrated interventions in addressing the complexities of post-deployment health. Study Overview Population: 41 U.S. military...
- [Repurposing Ketamine to Treat Cocaine Use Disorder: AI Prediction, Clinical Validation, and Mechanistic Insights](https://avyia.com/repurposing-ketamine-for-cocaine-use-disorder/): A 2023 study published in the journal Addiction presents a multifaceted investigation into repurposing ketamine as a treatment for cocaine use disorder (CUD), combining artificial intelligence (AI)-based prediction, expert clinical validation, and biological mechanism modeling. The study, available via Wiley Online Library, is a landmark example of translational research that bridges data science, clinical evidence, and neuropharmacology. The findings strongly suggest that ketamine may play a key role in reducing cocaine cravings and relapse, offering new hope for one of the most treatment-resistant substance use disorders. Study Overview Title: Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based...
- [AI-Based Study Links Ketamine to 2–4× Higher Remission in Cocaine Use Disorder](https://avyia.com/ketamine-for-cocaine-use-disorder/): An innovative study using artificial intelligence (AI) to analyze real-world patient data has found that ketamine treatment is associated with a 2 to 4 times higher likelihood of remission in individuals with cocaine use disorder (CUD). Reported by Psychedelic Spotlight, the research combines advanced machine learning algorithms with clinical outcomes data to uncover previously underappreciated effects of ketamine in addiction medicine. This represents one of the first AI-powered investigations into the effectiveness of ketamine for stimulant addiction — a domain where traditional treatment options remain limited and often ineffective. Study Overview Source: Reported by Psychedelic Spotlight, based on recent AI-powered...
- [Ketamine and Addiction: Alpha Psychiatry 2024 Review Shows Reduced Cravings and Relapse](https://avyia.com/ketamine-and-addiction-alpha-psychiatry-2024-review/): A 2024 narrative review published in Alpha Psychiatry explores ketamine’s growing role in the treatment of substance use disorders (SUDs) — including alcohol, opioids, cocaine, and cannabis. The review compiles findings from preclinical research, clinical trials, and case studies, showing that ketamine may significantly reduce cravings, substance use frequency, and relapse risk across a range of addictions. As psychedelic-assisted treatments gain traction, this review positions ketamine as one of the most promising candidates for neurobiological and psychological disruption of addiction cycles. Review Overview Publication: Alpha Psychiatry, 2024 Type: Narrative clinical review Focus: Ketamine’s efficacy and mechanisms in managing addictive behaviors...
- [Systematic Review: Ketamine Shows Short-Term Relief for Depression with Enhanced Outcomes When Combined with Cognitive Behavioral Therapy](https://avyia.com/ketamine-and-cbt-for-depression/): A 2023 systematic review published in Cureus has confirmed that ketamine offers rapid, short-term symptom relief in depressive and anxiety-related disorders, with notably stronger and more durable outcomes when used alongside Cognitive Behavioral Therapy (CBT). This synthesis of multiple studies reinforces the growing clinical consensus that ketamine works best when integrated with psychotherapeutic modalities, rather than used in isolation. Drawing from both controlled trials and real-world treatment programs, the review addresses ketamine’s immediate efficacy, duration of benefit, and its potential when paired with structured psychological interventions. Review Highlights Publication: Cureus, 2023 Scope: Systematic review of studies assessing ketamine monotherapy vs....
- [Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression](https://avyia.com/ketamine-for-bipolar-depression/): A pivotal real-world study published in Bipolar Disorders (Wiley, 2022) provides compelling evidence that repeated ketamine infusions offer significant clinical benefit for individuals with treatment-resistant bipolar depression (TRBD). Conducted in naturalistic clinical settings, the study validates ketamine’s effectiveness outside of tightly controlled trials — a major step toward its integration into broader psychiatric practice. The findings offer hope for patients who have exhausted standard mood stabilizers, antidepressants, and psychotherapy with limited or no success. Study Summary Title: Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression Authors: Irwin et al. Published in: Bipolar Disorders, 2022 Design: Open-label, observational study...
- [Ketamine-Assisted Psychotherapy for Bipolar Depression: Rapid Relief Within 40 Minutes](https://avyia.com/ketamine-assisted-psychotherapy-for-bipolar-depression/): A recent clinical review of ketamine-assisted psychotherapy (KAP) has spotlighted its transformative potential in treating depressive and suicidal symptoms in individuals with bipolar disorder. The review highlights rapid improvements, often emerging within 40 minutes post-treatment, particularly in patients unresponsive to conventional mood stabilizers and antidepressants. By combining the fast-acting neurobiological effects of ketamine with the deep psychological insights unlocked through therapy, KAP is emerging as a powerful new tool in the management of bipolar depression — one of the most treatment-resistant subtypes of mood disorders. Overview of the Review Focus: Ketamine-assisted psychotherapy (KAP) for bipolar I and II depression Data...
- [At-Home Ketamine via Telehealth: Large Study Shows Significant Anxiety Improvement](https://avyia.com/at-home-ketamine-for-anxiety/): A groundbreaking study published in the Journal of Affective Disorders has demonstrated the effectiveness of at-home ketamine treatment administered via telehealth for patients with anxiety-related disorders. In one of the largest real-world samples to date (n ≈ 1,247), the study found that 62.9% of participants experienced significant improvement in anxiety symptoms after just four weeks of treatment. This study highlights not only the clinical potential of ketamine but also its scalability and accessibility through remote medicine — a growing priority in post-pandemic mental health care. Study Overview Publication: Journal of Affective Disorders, 2022–2023 Study Type: Observational analysis of at-home treatment...
- [Systematic Review and Meta-Analysis: Ketamine Provides Rapid Relief for Anxiety Disorders](https://avyia.com/ketamine-for-anxiety-disorders/): A 2022 systematic review and meta-analysis has confirmed that ketamine produces rapid and significant reductions in anxiety symptoms, regardless of delivery method — whether intravenous (IV), intramuscular (IM), or oral. Published in peer-reviewed journals and summarized in clinical repositories like PubMed Central and Wikipedia, this comprehensive analysis provides strong evidence that ketamine could emerge as a powerful alternative for individuals suffering from various anxiety disorders. Study Overview Type: Systematic review and meta-analysis Publication year: 2022 Total studies included: 14 studies (including randomized controlled trials and observational designs) Sample size: Over 600 individuals across different anxiety diagnoses Conditions studied: Generalized Anxiety...
- [Ketamine for Treatment of PTSD: State of the Field Review](https://avyia.com/ketamine-for-ptsd-treatment-state-of-the-field-review/): A comprehensive review published in Frontiers in Psychiatry titled “Ketamine for the Treatment of Post-Traumatic Stress Disorder: State of the Field” (PMC10316217) offers an in-depth exploration of ketamine’s evolving role in managing PTSD. The review synthesizes clinical trials, translational research, and mechanistic theories, providing a critical benchmark for understanding where ketamine stands in the psychiatric treatment landscape. This state-of-the-field article confirms that ketamine — once limited to anesthesia and experimental use — is now a serious therapeutic contender for trauma-related disorders. Overview of the Review Publication: Frontiers in Psychiatry, 2023 Authors: Multidisciplinary team of psychiatrists, neuroscientists, and pharmacologists Focus: A...
- [Ketamine Infusion Study in Patients with Comorbid PTSD and TRD: Remarkable Remission Rates](https://avyia.com/ketamine-for-ptsd-and-depression/): A small but powerful study of patients with both post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) has revealed outstanding therapeutic outcomes following ketamine infusion therapy. In just two weeks, participants showed a dramatic 80% remission rate in PTSD symptoms and a 93% response rate in TRD — underscoring ketamine’s dual-action potential in complex psychiatric cases. Published on PubMed Central and widely discussed in patient communities such as Reddit, the study shines a spotlight on a subgroup of patients who are often the hardest to treat and most at risk for suicide, functional impairment, and chronic disability. Study Design and...
- [Narrative Review: Ketamine as an Adjunct Treatment for PTSD](https://avyia.com/ketamine-as-adjunct-for-ptsd/): A growing body of clinical narrative reviews has emphasized ketamine’s potential as a safe, effective, and durable adjunct treatment for post-traumatic stress disorder (PTSD). Drawing from a range of clinical experiences, open-label trials, and real-world observations, these reviews help bridge the gap between controlled research and frontline psychiatric practice. This emerging perspective supports ketamine not just as a standalone intervention, but as a complementary therapy that can enhance trauma-focused psychotherapy, improve patient responsiveness, and stabilize those at risk of treatment dropout. Overview of the Narrative Review Scope: Integrates clinical data, case reports, observational studies, and expert opinion Focus: Evaluates ketamine’s...
- [Ketamine for PTSD: Meta-Analysis Shows Promising Symptom Relief](https://avyia.com/ketamine-for-ptsd/): A comprehensive systematic review and meta-analysis of 10 studies — including 5 randomized controlled trials (RCTs) — has confirmed that ketamine infusions provide significant symptom relief in patients with post-traumatic stress disorder (PTSD). With an average effect size of approximately 0.25, the evidence supports ketamine as a promising alternative intervention for individuals unresponsive to conventional trauma therapies. Published across platforms such as PubMed, PMC, and summarized in resources like Wikipedia, this growing body of research highlights ketamine’s emerging role in trauma-focused psychiatry. Study Overview Review Type: Systematic review and meta-analysis Total studies analyzed: 10 (including 5 high-quality RCTs) Participants: Adults...
- [Safe, Low-Cost Ketamine: A Promising Treatment for Severe Depression](https://avyia.com/low-cost-ketamine-for-severe-depression/): New clinical data confirm that safe, low-cost ketamine is not only effective but also well-tolerated for people living with severe depression, particularly those who have not responded to standard treatments. With higher remission and response rates than placebo, these findings are shaping the next generation of affordable and scalable mental health care. Supported by research from ScienceDaily, PMC, and The Financial Times, the evidence builds on decades of ketamine research and solidifies its role in modern psychiatry. Study Highlights Type: Randomized, placebo-controlled trial Participants: Adults with severe or treatment-resistant depression Treatment: Low-dose, generic racemic ketamine, administered intravenously or via other...
- [KADS Trial: Subcutaneous Ketamine Proves Effective for Treatment-Resistant Depression](https://avyia.com/subcutaneous-ketamine-for-depression/): A recent active-controlled trial using subcutaneous ketamine injections over four weeks has demonstrated strong efficacy and safety in patients with treatment-resistant depression (TRD). Known as the KADS trial (Ketamine for Adult Depression Study), this study provides new insights into alternative delivery methods that could simplify and expand access to ketamine-based treatments. Published in peer-reviewed clinical sources and discussed in public forums including PubMed and Reddit, the KADS trial is an important milestone that underscores both the clinical viability and practical advantages of subcutaneous ketamine delivery. Study Highlights Trial type: Active-controlled, randomized clinical trial Duration: 4 weeks Population: Adults diagnosed with...
- [UNSW Low-Cost Ketamine Trial: A Game Changer for Depression Treatment](https://avyia.com/low-cost-ketamine-for-depression/): A new large-scale trial conducted by researchers at the University of New South Wales (UNSW) has added powerful evidence to the case for ketamine as a frontline treatment for treatment-resistant depression (TRD). What makes this trial especially noteworthy is not just the outcomes — which were impressive — but also the cost-effective approach that has serious implications for global mental health accessibility. Published in The Lancet, and covered widely in ScienceDaily, SciTechDaily, and other outlets, the trial demonstrated that low-cost, generic ketamine was highly effective in treating patients who had failed to respond to conventional antidepressants. The findings advocate for...
- [NEJM Study: Ketamine vs. ECT – A New Era in Treating Depression](https://avyia.com/ketamine-vs-ect-for-depression/): A groundbreaking clinical trial published in the New England Journal of Medicine (NEJM) has reignited the conversation around how we treat severe, treatment-resistant depression. The study directly compared the effectiveness of IV ketamine infusions with the long-established gold standard: electroconvulsive therapy (ECT). With 403 participants enrolled, the results challenge long-held assumptions about ECT’s supremacy and elevate ketamine’s role in modern psychiatric care. Trial Overview Study design: Randomized, non-inferiority trial  Participants: 403 adults with treatment-resistant major depressive disorder (MDD)  Interventions:  Ketamine group: IV ketamine administered twice per week for 3 weeks  ECT group: Standard bilateral ECT administered 2–3 times weekly  Outcome...
- [Racemic Ketamine for Depression: What 49 Clinical Trials Reveal About Its Effectiveness and Safety](https://avyia.com/racemic-ketamine-depression-clinical-trials/): Major depressive disorder (MDD) continues to be a leading cause of disability worldwide, affecting over 280 million people according to the World Health Organization. For many, first-line treatments such as SSRIs, SNRIs, or cognitive behavioral therapy provide some relief. However, for up to 30% of individuals, these traditional approaches are not enough. They suffer from what’s termed treatment-resistant depression (TRD) — a form of depression that persists despite trying two or more antidepressant treatments. This treatment gap has fueled interest in novel, fast-acting therapies, with ketamine at the forefront. Once known mainly as an anesthetic and recreational drug, racemic ketamine...
- [Unlocking Relief from PTSD and Chronic Pain: What AJ’s Ketamine Microdosing Journey Reveals](https://avyia.com/ketamine-microdosing-ptsd-pain-relief/): [vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”] Authors:  Jason Chang, DNP, ARNP-C Affiliations:  AVYIA [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]Corresponding Author/Contact:  jason.chang@avyia.com[/vc_column_text][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit”...
- [Breaking Through in India: Ketamine Therapy Demonstrates Sustained Relief in Severe Depression](https://avyia.com/ketamine-severe-depression-india-study/): In the clinical study Efficacy of ketamine therapy in the treatment of depression by Mandal, Sinha, and Goyal (2019), researchers evaluated the impact of ketamine therapy in treating severe depression among a unique group: drug-free, treatment-naïve male patients in India. The results were clear and compelling—ketamine showed rapid and sustained antidepressant and anxiolytic effects, beginning within the first hour and extending up to a month post-treatment. Major depressive disorder (MDD) remains one of the most burdensome mental illnesses globally, especially in regions where psychiatric care may be less accessible or stigmatized. The emergence of ketamine as a rapid-acting intervention has...
- [Ketamine's Antidepressant Efficacy in MDD and Bipolar Depression: A Meta-Analytic Review](https://avyia.com/ketamine-mdd-bipolar-meta-analysis/): In the systematic review and meta-analysis Ketamine as a Novel Treatment for Major Depressive Disorder and Bipolar Depression by Lee et al. (2015), researchers consolidated findings from six randomized, placebo-controlled trials to evaluate ketamine’s short-term efficacy for depressive symptoms in individuals diagnosed with major depressive disorder (MDD) and bipolar depression (BPAD). This quantitative synthesis provides some of the strongest early evidence supporting ketamine as a fast-acting and effective intervention for mood disorders resistant to conventional treatment. A Closer Look at the Meta-Analysis The meta-analysis included six randomized controlled trials (RCTs) conducted up to September 2013. All studies involved participants with...
- [Optimizing Ketamine Frequency: A Double-Blind Study on Dosing Strategies in Treatment-Resistant Depression](https://avyia.com/ketamine-dosing-frequency-trd-study/): In the landmark study A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression by Singh et al. (2016), researchers explored how frequently ketamine should be administered to sustain its powerful antidepressant effects in patients with treatment-resistant depression (TRD). This pivotal research sought to answer a crucial question: Does dosing frequency matter when delivering intravenous ketamine? Treatment-resistant depression poses a serious clinical challenge. Many patients fail to respond to multiple lines of pharmacological therapy, leaving them vulnerable to chronic symptoms and a reduced quality of life. Ketamine, a fast-acting NMDA receptor antagonist, has garnered attention for...
- [Ketamine Shows Dose-Dependent Relief for Refractory Anxiety Disorders](https://avyia.com/ketamine-dose-response-anxiety-treatment/): In the study Ketamine’s dose-related effects on anxiety symptoms in patients with treatment-refractory anxiety disorders by Glue et al. (2017), researchers explored whether ketamine—long known for its rapid antidepressant properties—could also alleviate symptoms in patients suffering from chronic, treatment-resistant anxiety. Their findings revealed that ketamine, administered in ascending doses, rapidly reduced anxiety within an hour, with effects lasting up to seven days. This small but important study supports the growing hypothesis that anxiety and depressive disorders may share overlapping neurobiological features and that ketamine’s unique mechanism of action may benefit both. Study Overview and Patient Demographics The open-label trial included...
- [Extending Ketamine's Reach: Can Exposure-Based CBT Sustain Obsessive-Compulsive Disorder Relief?](https://avyia.com/ketamine-cbt-ocd-treatment-extension/): In the open-label trial Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? by Rodriguez et al. (2016), researchers investigated whether cognitive behavioral therapy (CBT) could prolong the rapid symptom relief provided by ketamine in patients with obsessive-compulsive disorder (OCD). This study offers preliminary but promising insights into combining pharmacological and psychological treatments to optimize therapeutic outcomes in treatment-resistant OCD. OCD is a chronic psychiatric disorder marked by intrusive thoughts and repetitive behaviors, often resistant to standard interventions. While ketamine has demonstrated fast-acting reductions in obsessive symptoms, these effects are typically short-lived. The potential synergy between ketamine’s...
- [Breaking the Cycle: How a Single Ketamine Infusion Rapidly Reduces Suicidal Thoughts](https://avyia.com/single-ketamine-infusion-suicidal-thoughts/): In the landmark meta-analysis The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation by Wilkinson et al. (2018), researchers investigated whether a single intravenous (IV) dose of ketamine could reduce suicidal ideation in individuals suffering from depression. Their findings were groundbreaking: ketamine rapidly reduced suicidal thoughts within 24 hours, with sustained effects for up to one week. This result represents a significant shift in the treatment paradigm for acute suicidal ideation, where conventional antidepressants typically require weeks to take effect. Suicidal ideation is a psychiatric emergency with limited pharmacological options for immediate relief. Traditional antidepressants, including SSRIs...
- [Restoring Calm: Maintenance Ketamine Therapy Offers Hope for Severe Anxiety Disorders](https://avyia.com/ketamine-maintenance-therapy-anxiety/): In the study Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalized anxiety and social anxiety disorders by Glue et al. (2018), researchers explored the long-term effects of ketamine as a maintenance therapy for individuals suffering from chronic and treatment-resistant anxiety. The findings offer new hope: weekly subcutaneous injections of ketamine significantly reduced anxiety symptoms, were well tolerated, and improved patients’ day-to-day functioning. Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD) are among the most persistent and disabling mental health conditions, particularly when resistant to conventional treatments like SSRIs or cognitive-behavioral therapy. The promise of ketamine—a...
- [Dual Relief in Focus: Repeated Ketamine Infusions Ease PTSD and Depression Symptoms](https://avyia.com/ketamine-ptsd-depression-comorbid-treatment/): In the open-label clinical study Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression by Albott et al. (2018), researchers examined the therapeutic impact of intravenous ketamine in patients grappling with both posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD). The results were compelling: repeated ketamine infusions led to rapid, substantial, and sustained symptom reduction in both conditions. PTSD and TRD represent some of the most difficult psychiatric conditions to treat, and their co-occurrence amplifies functional impairment, complicates recovery, and increases the risk of suicide. Traditional pharmacologic strategies often fall short for such...
- [Refining the Dose: Intravenous Ketamine as Adjunctive Therapy for Treatment-Resistant Depression](https://avyia.com/ketamine-dose-treatment-resistant-depression/): In the double-blind clinical trial Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) by Fava et al. (2020), researchers sought to determine the most effective subanesthetic dose of intravenous ketamine for patients with treatment-resistant depression. The findings confirmed that the 0.5 mg/kg and 1.0 mg/kg doses were significantly more effective than lower doses or placebo, particularly in achieving rapid antidepressant effects. Treatment-resistant depression (TRD) continues to challenge clinicians, often requiring innovative solutions beyond first-line pharmacological treatments. Ketamine, with its rapid-onset action and novel glutamatergic mechanism, offers a unique adjunctive option for patients who have...
- [Restoring Hope: Repeated Ketamine Infusions Significantly Reduce Suicidal Ideation in Veterans with PTSD and MDD](https://avyia.com/ketamine-suicidal-ideation-ptsd-mdd-veterans/): In the clinical report Improvement in suicidal ideation after repeated ketamine infusions by Albott et al. (2019), a groundbreaking finding emerged: repeated doses of intravenous ketamine led to rapid and sustained reductions in suicidal ideation (SI) among veterans suffering from both posttraumatic stress disorder (PTSD) and major depressive disorder (MDD). This study provides strong preliminary support for ketamine’s role as a life-saving intervention in a population for whom traditional antidepressants and therapeutic interventions may fall short. Suicidal ideation remains a major concern among individuals with co-occurring PTSD and depression. Despite increasing awareness and available treatment options, many patients experience persistent...
- [Reclaiming Calm: Ketamine's Potential Role in Treating Resistant PTSD](https://avyia.com/ketamine-ptsd-treatment-resistant/): In the review article Ketamine as treatment for post-traumatic stress disorder: A Review by Liriano, Hatten, and Schwartz (2019), researchers examined the growing evidence behind ketamine’s potential as a rapid-acting intervention for post-traumatic stress disorder (PTSD). As conventional therapies often fail to provide full remission for many individuals, ketamine emerges as a hopeful alternative in cases of treatment-resistant PTSD. PTSD is a chronic and debilitating condition marked by intrusive memories, hyperarousal, and emotional numbness, often following trauma. While selective serotonin reuptake inhibitors (SSRIs) remain the only FDA-approved class of medications for PTSD, they have limited efficacy for a significant subset...
- [Rewiring the Reward Circuit: How Ketamine Enhances Emotional Processing in Depression](https://avyia.com/ketamine-reward-circuit-depression/): In the study Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder by Sterpenich et al. (2019), researchers explored how a single ketamine infusion reshapes the brain’s reward and emotional response circuitry in patients with treatment-resistant major depressive disorder (TRD). The results are striking: ketamine not only improved mood but also reactivated underperforming mesolimbic systems responsible for processing positive and negative stimuli—shifting the brain toward a more responsive and hopeful outlook. This research underscores ketamine’s evolving role in psychiatric care, not just as a fast-acting antidepressant, but as a tool for neuroplasticity...
- [Rewriting the Future: Ketamine's Promise for Treatment-Resistant Mood Disorders](https://avyia.com/ketamine-treatment-resistant-mood-disorders/): In the study Ketamine for Treatment-Resistant Mood Disorders, researchers underscore a pivotal turning point in psychiatric treatment. This body of work highlights how ketamine—a medication originally developed as an anesthetic—has emerged as a fast-acting agent capable of relieving symptoms of major depressive disorder (MDD) and bipolar depression, particularly in individuals who have not responded to traditional therapies. Treatment-resistant depression (TRD) affects nearly one-third of patients diagnosed with MDD. Standard antidepressants can take weeks to show results and often fail to produce full remission. The need for new approaches has never been more pressing, and ketamine has emerged as a beacon...
- [Breaking Through in India: Ketamine Therapy Demonstrates Sustained Relief in Severe Depression](https://avyia.com/india-ketamine-therapy-severe-depression/): In the clinical study titled Efficacy of ketamine therapy in the treatment of depression published in the Indian Journal of Psychiatry, researchers Mandal, Sinha, and Goyal explored whether subanesthetic doses of intravenous ketamine could produce rapid and sustained antidepressant effects in individuals with severe depression. With treatment-resistant depression posing a serious challenge in India and worldwide, this study offers compelling evidence that ketamine may offer not only immediate symptom relief but also durable improvements extending weeks beyond the final dose. For decades, traditional antidepressants have been the mainstay in treating major depressive disorder (MDD). However, these therapies often take weeks...
- [Stopping the Spiral: Ketamine Offers Emergency Relief for Acute Suicidal Ideation](https://avyia.com/ketamine-acute-suicidal-ideation-emergency-relief/): In the proof-of-concept trial Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial, researchers explored whether a single intravenous infusion of ketamine could provide rapid relief for individuals presenting to the emergency department with severe suicidal ideation. This small but important study is among the first to investigate ketamine’s potential as a front-line intervention in crisis scenarios, with a particular focus on timing, efficacy, and safety. The urgency of treating acute suicidal ideation cannot be overstated. Emergency departments often serve as a first point of contact for patients in distress, but traditional pharmacologic treatments...
- [A Promising Pattern: Meta-Analysis Reveals Strong, Sustained Antidepressant Effects of Ketamine in Treatment-Resistant Depression](https://avyia.com/ketamine-meta-analysis-trd-relief/): A Promising Pattern: Meta-Analysis Reveals Strong, Sustained Antidepressant Effects of Ketamine in Treatment-Resistant Depression In the meta-analysis Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials, researchers pooled data from 20 randomized controlled trials (RCTs) to evaluate the antidepressant potential of ketamine in patients with unipolar and bipolar depression. The results are both compelling and clinically significant: a single dose of ketamine produced rapid reductions in depressive symptoms, and repeated dosing helped sustain these improvements over several weeks. This comprehensive synthesis of clinical evidence provides robust support for ketamine’s role...
- [Resetting the Circuitry: Prolonged Ketamine Infusions Show Sustained Benefits for Treatment-Resistant Depression](https://avyia.com/prolonged-ketamine-infusion-trd/): Resetting the Circuitry: Prolonged Ketamine Infusions Show Sustained Benefits for Treatment-Resistant Depression In the open-label study Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression by Siegel et al. (2021), researchers explored the effects of extended ketamine infusion on brain function and symptom relief in individuals with treatment-resistant depression (TRD). Their findings point to a novel therapeutic strategy: a 96-hour ketamine infusion that produces rapid, significant, and sustained antidepressant effects, along with measurable brain connectivity changes. This innovative approach not only relieves depressive symptoms in some of the most difficult-to-treat patients, but it also uncovers key...
- [Breaking the Cycle: Repeated Ketamine Infusions Show Promise for Chronic PTSD](https://avyia.com/ketamine-infusions-chronic-ptsd-treatment/): Study Design and MethodoBreaking the Cycle: Repeated Ketamine Infusions Show Promise for Chronic PTSD In the pivotal study A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder by Feder et al. (2021), researchers investigated the impact of multiple ketamine infusions on individuals living with long-term PTSD. The findings mark a significant advancement in the treatment landscape for trauma-related disorders—especially for those unresponsive to standard interventions. Using a rigorous double-blind, randomized design, the study found that repeated doses of intravenous ketamine not only reduced PTSD symptoms significantly but also improved depressive symptoms, with a strong response rate...
- [Rewiring Hope: Ketamine and the Rise of Rapid-Acting Antidepressants](https://avyia.com/ketamine-rapid-acting-antidepressants-future/): In the landmark review Ketamine and the Future of Rapid-Acting Antidepressants by Lace M. Riggs and Todd D. Gould (2021), the authors explore the evolution of antidepressant therapies and the groundbreaking role of ketamine in transforming psychiatric care. For decades, patients with major depressive disorder (MDD) have relied on standard antidepressants like SSRIs and SNRIs. These medications often take weeks to show benefit—and for many, they fail to work altogether. In sharp contrast, ketamine can rapidly alleviate depressive symptoms within hours, including in patients previously considered treatment-resistant. This review not only discusses ketamine’s history and clinical potential, but also outlines...
- [Mapping Recovery: Neuroimaging Markers Predicting Ketamine Response in PTSD](https://avyia.com/neuroimaging-ketamine-response-ptsd-biomarker/): In the study Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: Preliminary evidence (Norbury et al., 2021), researchers explored how brain imaging could offer clues into why some individuals with posttraumatic stress disorder (PTSD) respond to ketamine treatment while others do not. By examining brain activity through functional neuroimaging, the team identified promising neural correlates—specifically the functional connectivity between the amygdala and the ventromedial prefrontal cortex (vmPFC)—that may predict how well a person with PTSD will respond to repeated ketamine infusions. The findings suggest a neurological basis for ketamine’s therapeutic effects, advancing the push toward biomarker-informed...
- [Breaking Through the Wall: Expanding Options for Treatment-Resistant Depression](https://avyia.com/treatment-resistant-depression-options-esketamine-psilocybin/): In the article Treatment resistant depression at a glance with traditional, first line antidepressant treatments, as well as a review of the evidence behind esketamine, psilocybin and pramipexole (Kverno & Mangano, 2021), the authors offer a concise yet impactful overview of how clinicians can address one of psychiatry’s most pressing challenges: treatment-resistant depression (TRD). Defined as a major depressive episode that does not remit after at least two adequate trials of first-line antidepressant medications, TRD affects nearly 30% of patients seeking treatment for depression. The article outlines the core features of TRD, explores its neurobiological underpinnings, and reviews the emerging...
- [Targeting the Depths: How Low-Dose Ketamine Offers Rapid Relief for Double Depression](https://avyia.com/low-dose-ketamine-double-depression-treatment/): In the study Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (Chen et al., 2021), researchers investigated the antidepressant and antisuicidal effects of ketamine in a particularly challenging subset of patients: those suffering from treatment-resistant double depression. This condition involves the coexistence of major depressive episodes superimposed on chronic dysthymia, and is notoriously difficult to treat with conventional antidepressants. The study provides evidence that a single infusion of 0.5 mg/kg ketamine can lead to rapid symptom improvement in both depressive severity and suicidal ideation in this population. These results offer...
- [Rewiring Emotional Circuits: How Ketamine Calms Overactive Brain Regions in Depression](https://avyia.com/ketamine-subgenual-cingulate-depression-fmri-study/): In the study Ketamine normalizes subgenual cingulate cortex hyper-activity in depression (Morris et al., 2020), researchers explore a key neurobiological mechanism underlying ketamine’s fast-acting antidepressant effects. By focusing on the subgenual anterior cingulate cortex (sgACC)—a brain region often overactive in major depressive disorder (MDD)—this research reveals how a single ketamine infusion can dampen maladaptive brain responses to emotional stimuli. These findings not only confirm ketamine’s antidepressant potential but also provide insight into how specific brain circuits contribute to symptoms like anhedonia and anxiety. Understanding how ketamine affects the sgACC is crucial, as this region has long been implicated in emotional...
- [Restoring Balance: Dose-Dependent Effects of Ketamine on Depression in PTSD-Resistant Veterans](https://avyia.com/ketamine-depression-ptsd-veterans-dose-trial/): In the clinical trial Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active-duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial, researchers examined how different doses of ketamine affect veterans and active-duty military personnel suffering from treatment-resistant PTSD. This study stands out not only for its large sample size and methodological rigor, but also for its nuanced findings: while ketamine failed to significantly reduce PTSD symptoms compared to placebo, it did produce rapid, dose-dependent antidepressant effects, particularly at the standard 0.5 mg/kg dose. With mental health challenges disproportionately affecting military populations, the need for...
- [Rewiring Consciousness: How Ketamine Reorganizes Neuronal Activity in the Brain](https://avyia.com/ketamine-brain-neuronal-rewiring-consciousness/): In the groundbreaking study Ketamine triggers a switch in excitatory neuronal activity across neocortex (Cichon et al., 2022), researchers uncovered how ketamine—a drug often used in anesthesia and increasingly explored for psychiatric applications—alters the fundamental way neurons in the brain communicate. This discovery not only sheds light on the mysterious dissociative state induced by ketamine but also deepens our understanding of consciousness, perception, and treatment-resistant mental health conditions. The research, conducted in mice, demonstrated that ketamine fundamentally reorganizes neural circuits across the neocortex. Rather than simply dampening overall activity or boosting it globally, ketamine selectively suppresses some previously active neurons...
- [Productivity and Performance: Nutrition Hacks for Busy Professionals](https://avyia.com/nutrition-hacks-busy-professionals/): In today’s fast-paced world, “Productivity and Performance: Nutrition Hacks for Busy Professionals” is more than a wellness buzz phrase—it’s a survival strategy. For working professionals juggling deadlines, multitasking, and cognitive workloads, fatigue, brain fog, and burnout often feel inevitable. Whether it’s low energy by midday or difficulty staying focused in meetings, these symptoms aren’t just annoyances—they’re red flags your body is running low on fuel, and your brain is short on nutrients. While stress, poor sleep, and sedentary lifestyles play their roles, nutrition is often the hidden culprit—and your best ally. Smart dietary choices, even small ones, can profoundly affect...
- [Review of the Science and Meta-Analysis: Effectiveness of a Single Dose of Ketamine Therapy on Suicidal Ideation](https://avyia.com/single-dose-ketamine-suicidal-ideation-meta-analysis/): Ketamine, traditionally known as an anesthetic, has emerged in recent years as a powerful therapeutic option for rapid relief from severe depressive symptoms and suicidal ideation. Among the most compelling evidence comes from the study titled “The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis” by Wilkinson et al. (2018), which evaluates the impact of a single intravenous (IV) dose of ketamine on patients experiencing suicidal thoughts. This article reviews that study’s design, findings, and clinical implications in a clear, accessible format for both professionals and the broader wellness...
- [Antidepressant, Mood-Stabilizing, and Procognitive Effects of Very Low Dose Sublingual Ketamine in Refractory Depression: A Deep Dive into New Possibilities](https://avyia.com/vlds-sublingual-ketamine-refractory-depression-study/): Introduction: Antidepressant, Mood-Stabilizing, and Procognitive Effects of Very Low Dose Sublingual Ketamine in Refractory Unipolar and Bipolar Depression In recent years, ketamine has emerged as one of the most promising therapies in psychiatry. Its rapid-acting effects have transformed how we understand and treat mood disorders, particularly in individuals with treatment-resistant depression. Among the most intriguing developments is the use of very low dose sublingual (VLDS) ketamine in managing refractory unipolar and bipolar depression. A pioneering study by Lara et al. (2013) titled “Antidepressant, Mood-Stabilizing, and Procognitive Effects of Very Low Dose Sublingual Ketamine in Refractory Unipolar and Bipolar Depression“ offers...
- [Ketamine Assisted Psychotherapy (KAP): A Comprehensive Review of Clinical Outcomes and Patient Demographics](https://avyia.com/ketamine-assisted-psychotherapy-kap-outcomes-study/): Introduction: Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy The search for innovative and effective treatments for mental health disorders continues to evolve, with ketamine emerging as a promising therapeutic agent. Ketamine Assisted Psychotherapy (KAP), which integrates the pharmacological effects of ketamine with structured psychotherapy, has shown significant promise in private clinical settings. One notable study by Dore et al. (2019) provides a comprehensive look into the real-world application of KAP, offering insights into patient demographics, clinical outcomes, and therapeutic implications. This article delves into the study’s findings and explores...
- [Ketamine Dose Study: Exploring Its Impact on Treatment-Resistant PTSD in Veterans](https://avyia.com/ketamine-dose-ptsd-study-veterans/): Introduction: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military For veterans and active-duty military personnel grappling with posttraumatic stress disorder (PTSD), treatment-resistant symptoms can persist despite standard interventions. A groundbreaking multi-center clinical trial, titled Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Abdallah et al., 2022), explores the potential of ketamine as a novel treatment option. This large-scale study offers new insights into ketamine’s effects not just on PTSD, but also on comorbid depression and...
- [NAD+ IV Therapy Benefits: A Complete Guide to Anti-Aging Therapy](https://avyia.com/nad-iv-therapy-benefits-anti-aging-guide/): Introduction: NAD+ IV Therapy Benefits — A Complete Guide to Anti-Aging Therapy For centuries, people have searched for the elusive “fountain of youth.” While reversing chronological age remains science fiction, modern research shows that it is very possible to reduce your metabolic age—the true marker of biological wear and tear. A 30-year-old and a 50-year-old might share the same number on their birthday cakes, but internally, they could be decades apart in health.1 That’s where NAD+ IV therapy comes in. Short for nicotinamide adenine dinucleotide, NAD+ is a coenzyme found in every living cell and is fundamental to processes like...
- [Science and Lifestyle Strategies for Healthy Aging](https://avyia.com/healthy-aging-science-lifestyle-strategies/): Introduction: Embracing Aging with Modern Science It is well-established that aging affects individuals differently. Some people maintain health and vitality well into their later years, while others experience early signs of decline. While genetics do play a role, scientific research confirms that lifestyle choices have a far more profound impact on how we age. Although aging is inevitable, science offers evidence-based strategies to slow biological aging, boost longevity, and maintain a high quality of life. This article explores the key biological mechanisms of aging and practical steps individuals can take to support healthy aging through diet, exercise, sleep, stress reduction,...
- [Tirzepatide vs. Semaglutide: A Value-for-Money Perspective in Type 2 Diabetes Weight Loss](https://avyia.com/tirzepatide-vs-semaglutide-cost-effective-weight-loss-t2d/): Introduction: Tirzepatide versus Semaglutide for Weight Loss in Patients with Type 2 Diabetes Mellitus — A Value for Money Analysis With the rising prevalence of type 2 diabetes and its strong correlation with obesity, pharmacological weight-loss strategies are becoming essential. Among the leading agents are tirzepatide and semaglutide, both GLP-1 receptor agonists with significant effects on body weight. But which drug offers the best value? The study by Azuri et al., published in Diabetes, Obesity and Metabolism in 2023, sought to compare these two treatments not just in terms of effectiveness, but cost-efficiency — quantifying the dollar amount required per...
- [Hangover Survival Guide: Causes, Remedies, and Impact on Health](https://avyia.com/hangover-survival-guide-causes-remedies-health/): Introduction: Understanding the Science Behind the Hangover Hangovers are a near-universal experience for individuals who occasionally indulge in alcohol. While alcohol is deeply embedded in social and cultural traditions across the world, excessive consumption—even if rare—often results in the unpleasant aftermath known as a hangover. Characterized by symptoms such as headaches, nausea, fatigue, and mental fog, a hangover can last from several hours to over a day. Surprisingly, despite its widespread occurrence, hangovers remain poorly understood by the medical community. Hangovers don’t necessarily reflect alcohol dependency; even those who drink occasionally can suffer severe symptoms after heavy consumption. This article...
- [Unlocking Psychedelics: How Celebrities Are Rewriting the Narrative](https://avyia.com/celebrities-psychedelics-mental-health-narrative/): Introduction: Is Ketamine Safe for Mental Health Treatment? In recent years, the world has witnessed a major shift in how psychedelics are perceived, and much of this transformation is being driven by high-profile celebrities. From Elon Musk’s candid use of ketamine to Amanda Feilding’s enduring research advocacy, these influential figures are helping reshape the global narrative around psychedelics. But is ketamine truly safe for mental health treatment? This article examines the evolving safety profile of ketamine, places it in historical context, and explores how celebrity advocacy is influencing public perception and policy reform. The Historical Context of Psychedelic Use To...
- [Ketamine for Mental Health: A Closer Look at Its Safety Compared to Traditional Medications](https://avyia.com/ketamine-safety-vs-traditional-mental-health-meds/): Introduction: Is Ketamine Safe for Mental Health Treatment? Is ketamine safe for mental health treatment? This is a question that has gained increasing relevance as ketamine garners attention for its rapid antidepressant effects. Once known primarily as a surgical anesthetic, ketamine is now at the forefront of psychiatric innovation. In this article, we’ll explore its safety profile, how it compares to other common medications, and what patients can expect when using ketamine for mental health treatment. A Proven Medical Track Record Ketamine’s medical use dates back to the 1960s when it was developed as an anesthetic. It has since earned...
- [Tirzepatide vs. Semaglutide: A Value-for-Money Perspective in Type 2 Diabetes Weight Loss](https://avyia.com/tirzepatide-vs-semaglutide-cost-effectiveness-diabetes/): Introduction: Tirzepatide versus Semaglutide for Weight Loss in Patients with Type 2 Diabetes Mellitus — A Value for Money Analysis With the rising prevalence of type 2 diabetes and its strong correlation with obesity, pharmacological weight-loss strategies are becoming essential. Among the leading agents are tirzepatide and semaglutide, both GLP-1 receptor agonists with significant effects on body weight. But which drug offers the best value? The study by Azuri et al., published in Diabetes, Obesity and Metabolism in 2023, sought to compare these two treatments not just in terms of effectiveness, but cost-efficiency — quantifying the dollar amount required per...
- [Semaglutide for Weight Loss in Non-Diabetic Obesity: A Meta-Analytic Overview of Efficacy and Safety](https://avyia.com/semaglutide-weight-loss-non-diabetic-obesity-review/): Introduction: Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes — A Systematic Review and Meta-Analysis Obesity continues to rise globally, necessitating evidence-based, long-term treatment strategies that are both effective and safe. For individuals with obesity who do not have type 2 diabetes, semaglutide has emerged as a promising intervention. The systematic review and meta-analysis titled “Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes“ by Tan et al., published in the Journal of the ASEAN Federation of Endocrine Societies in 2022, aims to clarify semaglutide’s therapeutic value in this specific population. This analysis...
- [Semaglutide for Long-Term Weight Management: Two-Year Insights from the STEP 5 Trial](https://avyia.com/semaglutide-step-5-long-term-weight-loss/): Introduction: Two-Year Effects of Semaglutide in Adults with Overweight or Obesity — The STEP 5 Trial With obesity posing a significant public health burden, long-term therapeutic strategies are essential. Semaglutide, a GLP-1 receptor agonist, has garnered considerable attention for its potent weight-loss effects in adults with obesity or overweight. The STEP 5 trial, titled “Two-Year Effects of Semaglutide in Adults with Overweight or Obesity“ by Garvey et al., published in Nature Medicine in 2022, provides critical insights into the prolonged safety and efficacy of semaglutide over a 104-week period. This randomized, double-blind, placebo-controlled study aimed to assess sustained outcomes in...
- [Tirzepatide and Weight Loss: A Systematic Review of Efficacy and Safety](https://avyia.com/tirzepatide-weight-loss-systematic-review/): Introduction: Weight Loss Efficiency and Safety of Tirzepatide—A Systematic Review As the global obesity epidemic continues to escalate, the medical community seeks treatments that offer both effectiveness and safety in reducing excess body weight. Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has shown considerable promise in clinical trials. The 2023 systematic review and meta-analysis titled “Weight Loss Efficiency and Safety of Tirzepatide“ by Lin et al., published in PLOS ONE, presents a comprehensive synthesis of the available evidence surrounding tirzepatide’s efficacy and safety profile. This review evaluated results from multiple clinical trials to determine how well tirzepatide performs...
- [Tirzepatide: A Weekly Injection Offering a New Horizon in Obesity Treatment](https://avyia.com/tirzepatide-weekly-injection-obesity-treatment/): Introduction: Tirzepatide Once Weekly for the Treatment of Obesity Obesity remains one of the most pressing public health challenges worldwide, contributing to serious complications such as diabetes, cardiovascular disease, and premature mortality. Traditional approaches—diet, exercise, and behavior modification—often fall short of delivering sustained results. Pharmacological interventions are gaining momentum, particularly those demonstrating durable, clinically significant weight loss with manageable side effects. The study titled “Tirzepatide Once Weekly for the Treatment of Obesity” by Jastreboff et al., published in the New England Journal of Medicine in 2022, evaluates a novel medication, tirzepatide, in a long-term clinical setting. The findings from the...
- [Prolonged Ketamine Infusion: A Promising Frontier for Lasting Remission in Treatment-Resistant Depression](https://avyia.com/prolonged-ketamine-infusion-trd-remission/): Introduction: Prolonged Ketamine Infusion Modulates Limbic Connectivity and Induces Sustained Remission of Treatment-Resistant Depression Treatment-resistant depression (TRD) remains a persistent challenge in psychiatric care, characterized by limited or no response to standard antidepressant therapies. In recent years, ketamine has emerged as a breakthrough agent due to its rapid and robust antidepressant effects. However, the question of how to extend these benefits beyond a few days or weeks has remained largely unanswered. A 2021 open-label, proof-of-principle study by Siegel et al., titled “Prolonged Ketamine Infusion Modulates Limbic Connectivity and Induces Sustained Remission of Treatment-Resistant Depression,” published in Psychopharmacology, explored an innovative...
- [At-Home Sublingual Ketamine Telehealth: Expanding Access to Effective Mental Health Treatment](https://avyia.com/at-home-sublingual-ketamine-telehealth/): Introduction: At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression As mental health concerns continue to rise globally, the need for accessible and effective treatment options becomes more urgent. Traditional antidepressants, while beneficial for some, often come with long delays before relief is felt and may not be effective for everyone. In this context, a novel 2022 study by Hull et al., published in the Journal of Affective Disorders, offers a promising new model of care: “At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and...
- [Single-Dose Ketamine for Suicidal Ideation: A Rapid Breakthrough in Crisis Psychiatry](https://avyia.com/single-dose-ketamine-suicidal-ideation/): Introduction: Review of the Science and Meta-Analysis to Study the Effectiveness of a Single Dose of Ketamine Therapy on Suicidal Ideation Suicidal ideation represents one of the most urgent and dangerous symptoms of major depressive disorder (MDD). Traditional antidepressants may take weeks to become effective, leaving individuals vulnerable during a critical window. In this context, the study “The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis“ by Wilkinson et al., published in the American Journal of Psychiatry in 2018, offers a groundbreaking perspective. This meta-analysis focused on evaluating the...
- [Ketamine Frequency Study: A New Path Forward in Treating Resistant Depression](https://avyia.com/ketamine-treatment-resistant-depression-study/): Introduction: Revisiting a Promising Approach to Treatment-Resistant Depression Treatment-resistant depression (TRD) remains one of the most difficult forms of depression to manage effectively. Despite the array of available antidepressants and therapies, many patients experience limited or no relief. This creates an urgent need for innovative treatments that work not only quickly but also sustainably. One study that has garnered attention for addressing this challenge is titled “A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression“ by Singh et al., published in the American Journal of Psychiatry in 2016. This landmark study sought to examine whether...
- [Ketamine for Suicidal Ideation: A Fast-Acting Intervention Backed by Science](https://avyia.com/ketamine-suicidal-ideation-treatment/): For decades, managing suicidal ideation has presented one of the greatest challenges in psychiatry. The urgency of such mental health crises often clashes with the slow onset of traditional antidepressants, leaving patients vulnerable during a critical window. However, scientific research is now illuminating a powerful and fast-acting alternative: ketamine. Originally developed as an anesthetic and long stigmatized as a recreational drug, ketamine has recently shown promising results in treating acute suicidal thoughts. A pivotal meta-analysis titled “The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis”, published in the American...
- [Retatrutide- Upcoming Revolution in Obesity Treatment](https://avyia.com/retatrutide-for-weight-loss/): Retatrutide is still in the development stages. However, it is pretty likely to be soon approved for managing obesity. When approved, it will become the first-ever drug belonging to the new class of drugs that are GLP-1, GIP, and Glucagon receptor agonists. It would be the first drug that acts on all these three receptors. Hence, it is expected to be one of the most potent weight loss drugs ever introduced by science. Drugs acting on these receptors are known to be safe, and hence, Retatrutide appears to be safe for prolonged use. It would be somewhat right to call...
- [Tirzepatide Emerges as the Most Potent Weight Loss Drug](https://avyia.com/tirzepatide-for-weight-loss/): We are living in exciting times. Finally, we are seeing the emerging new class of extremely safe and highly effective weight-loss drugs. Unlike previous drugs that could barely help lose a few pounds on prolonged use, this new class of drugs, to which tirzepatide belongs, can help shed significant body weight. Moreover, these new class of drugs have numerous benefits for endocrinal health. These drugs are well-tolerated and good for prolonged use. So, finally, there are drugs that can help meet body weight targets. In the last few decades, researchers have started looking at obesity very differently. Obesity is no...
- [Flab2Fab: Embracing Semaglutide’s Weight Loss Wonder](https://avyia.com/semaglutide-for-weight-loss/): Semaglutide is one of the most effective weight loss drugs ever discovered by science. It is highly effective and belongs to the new class of drugs called GLP-1 agonists. This article will explore every aspect of using semaglutide for weight loss, from efficacy to safety and everything in between. The drug has become a revolution in weight loss treatment. It is one of the most popular weight loss drugs. Its popularity is so great that its manufacturer is struggling to produce it in enough quantities. It is one of the biggest blockbuster drugs after the invention of Viagra.(1) It is...
- [Defying Despair: The Power of Ketamine in Suicide Intervention](https://avyia.com/ketamine-for-suicide-prevention/): In this article, we will explore various ways in which ketamine may help prevent suicides and reduce its risk. However, first, we need to understand the gravity of the problem and its causes. Suicide is not a disease but rather a result of prolonged despair. Severe or major depression is among the leading causes of suicides. However, suicide might occur for various other reasons. It mainly occurs due to mental health issues. Some individuals are overwhelmed with troubles, and they start idealizing suicide. Since suicide kills people, it is still a significant health concern. Figure 1 Suicide statistics – CDC...
- [Ketamine for Breaking Addiction Chains](https://avyia.com/ketamine-for-addiction-treatment/): Ketamine, a popular rave party drug, is also known to help break the addiction chain when used responsibly. This is not a surprise, as the pharmaceutical industry invented most street drugs, and they were meant to manage health conditions. Even drugs of natural origins, like opioids or cannabis, have many health benefits when used responsibly – however, they cause much harm if abused. So, the quote that the difference between the poison and remedy is in the dose remains as valid as ever. Addiction is quite a complex phenomenon. It is also essential not to associate it with just street...
- [Unlocking Relief: The Promise of Ketamine for Migraine Sufferers](https://avyia.com/ketamine-for-migraine-treatment/): Migraine headaches are pretty common, affecting 10% to as high as 20% of individuals in any population group. What is worrisome is that the cases of migraine headaches are rising. Yet, science is not fully sure of the cause of its rise. It means that a staggering number of people, that is, more than a billion individuals, are living with migraine headaches. People have known about migraine headaches for centuries. In some individuals, these pains can be very severe and debilitating. However, it is more important to realize that these are not just regular headaches. Migraine is a severe neurological...
- [From Despair to Hope: Ketamine’s Impact on Postpartum Depression Recovery](https://avyia.com/ketamine-for-postpartum-depression/): Postpartum depression (PPD) is a pretty common problem, and yet there is insufficient awareness about the condition. Almost every sixth women who gives childbirth experiences PPD to some extent, with some studies suggesting that PPD may affect as many as 20% of women.(1) As the name of the condition suggests, it occurs postpartum, that is, after giving birth. Most of these women are relatively healthy before giving birth, and they do not essentially show any signs of mental health issues. Of course, PPD’s risk is even higher in those prone to mental health issues, like women who were already experiencing...
- [Breaking Obsessions, Finding Freedom Ketamine Therapy for OCD Treatment](https://avyia.com/ketamine-for-ocd-treatment/): Obsessive-compulsive disorder (OCD) is a pretty common mental health issue affecting about 1-2% of people globally. Of course, real numbers might be much higher as many, if not most, are not seeking medical help for this relatively benign condition. Although the condition is not life-threatening, it causes much distress. If you are among those who cannot stop repeating certain actions for no reason, you might be living with the condition. The condition is pretty easy to diagnose. Most of those living with the condition are aware of their problem. Moreover, people around them can also notice that a person is...
- [Beyond the Nightmares Ketamine’s Role in PTSD Healing](https://avyia.com/ketamine-for-ptsd-treatment/): Most people have heard about PTSD these days. It is a condition characterized by nightmares. A condition that frequently occurs secondary to some emotional trauma. However, internal factors also play a role in disease development as people interpret the same situation differently. The condition is pretty common these days. Latest estimates suggest that about 6% of people are living with PTSD in the US. Further, it appears that the condition is relatively more common in women. Additionally, the condition is more likely to be reported in veterans.(1) Of course, most people experience some emotional trauma during their lives. However, many...
- [Unlocking Stability: The Ketamine Revolution in Bipolar Disorder Management](https://avyia.com/ketamine-for-bipolar-disorder/): As life becomes more stressful than before, an increasing number of people are developing mental health issues. Disease conditions that were rare a few decades back are common nowadays. One such mental health problem that is not uncommon these days is bipolar disorder. Studies suggest that about 2.8% of the US population, or about eight million people, is living with the condition.(1) Life can be pretty distressing for those living with bipolar disorder. Further, the condition also affects those living with the patients. The unpredictability of the mood is the hallmark of the condition. Hence, those living with the patient...
- [Ketamine: A New Horizon in the Battle Against Depression](https://avyia.com/ketamine-for-depression-treatment/): Depression and anxiety are the two most common emotional disorders. They might affect just anyone during their lifetime. US data suggests that, on average, about 18.5% of adults are living with depression. (1) Yes, those numbers are massive. Hence, researchers think that it is perhaps the most common mental health issue in the US. Moreover, compared to anxiety, it is a more severe disorder, and hence a need to find its effective treatment. It is difficult to understand why depression has become so common in the last few decades. Just by the middle of the last century, depression was described...
- [Ketamine’s Breakthrough Role in Treating Anxiety Disorders: A Paradigm Shift in Psychiatric Care](https://avyia.com/ketamine-for-anxiety-treatment/): Anxiety is the most common mental health or emotional disorder, affecting about 25% of the population globally. (1) These are massive numbers. What is worrisome is that the number of people complaining about severe anxiety is rising. Though many medications might help manage the condition, most treatments are insufficient and unsatisfactory. Thus, the search for effective treatment continues. Breakthrough ketamine therapy now offers hope, providing quick and prolonged relief. Emotional disorders like anxiety are more common in females. Most likely, female hormones make them prone to emotional disorders. (2) Anxiety is not essentially a disorder. It is normal for people...
- [Unlocking Hope for Chronic Depression: How Personalized Ketamine Titration Helped M&M Reclaim Her Life](https://avyia.com/personalized-ketamine-for-chronic-depression/): [vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”] Authors:  Jason Chang, DNP, ARNP-C Affiliations:  AVYIA [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]Corresponding Author/Contact:  jason.chang@avyia.com[/vc_column_text][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit”...
- [Transitioning from Macro-Dosing to Microdosing Ketamine for Anxiety and Mood Enhancement: The Case of RK](https://avyia.com/transitioning-from-macro-dosing-to-microdosing-ketamine-for-anxiety-and-mood-enhancement-the-case-of-rk/): [vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”] Authors:  Jason Chang, DNP, ARNP-C Affiliations:  AVYIA [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/2″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]Corresponding Author/Contact:  jason.chang@avyia.com[/vc_column_text][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit”...
- [Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.](https://avyia.com/ketamine-versus-ect-for-nonpsychotic-treatment-resistant-major-depression/): Anand, A et al. (2023).  Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.  N Engl J Med 2023;388:2315-25. DOI: 10.1056/NEJMoa2302399  Highlights: A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response. Patients with treatment-resistant major depression without psychosis were recruited and assigned in a 1:1 ratio to receive ketamine or ECT. During an initial 3-week treatment phase, patients received either ECT three times per week or ketamine (0.5 mg per kilogram of body weight over 40 minutes) twice per week. Results: A total of 403 patients underwent randomization...
- [<a href="https://clinicaltrials.gov/study/NCT01349231">Ketamine Infusion for Obsessive-Compulsive Disorder.</a>](https://avyia.com/ketamine-infusion-for-obsessive-compulsive-disorder/): Bloch MH.  Ketamine Infusion for Obsessive-Compulsive Disorder. ClinicalTrials.gov.  2014 June; https://clinicaltrials.gov/study/NCT01349231 Highlights: In a placebo-controlled study completed at Yale, a single dose of ketamine (0.5 mg/kg, intravenously) had rapid antidepressant effects in depressed patients. In these subjects, ketamine infusion produced mild psychotomimetic symptoms and euphoria that dissipated within 120 minutes, while the antidepressant effects of ketamine infusion emerged over the first 180 minutes and persisted over 72 hours. Fifty percent of depressed patients receiving ketamine were treatment responders at Day 3 compared to 12.5% in the placebo infusion group. These results have been replicated in a recent double-blind study performed at...
- [<a href = "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/1860851">Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder.</a>](https://avyia.com/efficacy-of-intravenous-ketamine-for-treatment-of-chronic-posttraumatic-stress-disorder-2/): Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A., Wan, L.-B., Iosifescu, D., &amp; Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry, 71(6), 681–688 Highlights: Objective: To test the efficacy and safety of a single intravenous subanesthetic dose of ketamine for the treatment of PTSD and associated depressive symptoms in patients with chronic PTSD. Proof-of-concept, randomized, double-blind, crossover trial comparing ketamine with an active placebo control, midazolam…Forty-one patients with chronic PTSD related to a range of...
- [Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder.](https://avyia.com/efficacy-of-intravenous-ketamine-for-treatment-of-chronic-posttraumatic-stress-disorder/): Highlights: Objective: To test the efficacy and safety of a single intravenous subanesthetic dose of ketamine for the treatment of PTSD and associated depressive symptoms in patients with chronic PTSD. Proof-of-concept, randomized, double-blind, crossover trial comparing ketamine with an active placebo control, midazolam…Forty-one patients with chronic PTSD related to a range of trauma exposures were recruited via advertisements. Interventions: IV infusion of ketamine (0.5 mg/kg) and midazolam (0.045 mg/kg). The primary outcome measure was change in PTSD symptom severity, measured using the Impact of Event Scale-Revised. Secondary outcome measures included the Montgomery-Asberg Depression Rating Scale, the Clinical Global Impression-Severity and -Improvement scales,...
- [Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.](https://avyia.com/rapid-antidepressant-effects-of-repeated-doses-of-ketamine-compared-with-electroconvulsive-therapy-in-hospitalized-patients-with-major-depressive-disorder/): Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 2014 Feb 28;215(2):355-61. doi: 10.1016/j.psychres.2013.12.008. Epub 2013 Dec 13. PMID: 24374115. Highlights: In this blind, randomized study, 18 patients with DSM-IV MDD were divided into two groups which received either three intravenous infusions of ketamine hydrochloride (0.5mg/kg over 45 min) or ECT on 3 test days (every 48 h). The primary outcome measure was the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS), which was used to...
- [Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.](https://avyia.com/augmentation-of-response-and-remission-to-serial-intravenous-subanesthetic-ketamine-in-treatment-resistant-depression/): Shiroma, Johns et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment-resistant depression” Journal of Affective Disorders. 2014 Feb;155:123-9. Highlights: In this study, we determined antidepressant response and remission to six consecutive ketamine infusions while maintaining stable doses of the antidepressant regimen. We also examined the trajectory of response and remission and the time to relapse among responders. TRD subjects had at least a 2-month period of stable dose of antidepressants. Subjects completed six IV infusions of 0.5 mg/kg ketamine over 40 min on a Monday–Wednesday–Friday schedule during a 12-day period participants meeting response criteria were monitored for...
- [Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept.](https://avyia.com/randomized-controlled-crossover-trial-of-ketamine-in-obsessive-compulsive-disorder-proof-of-concept/): Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., &amp; Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology, 38(12), 2475–2483. Highlights: Participants receiving ketamine first showed a significant rapid reduction in obsessions during the infusion that persisted until 1 week post-infusion compared with participants receiving a placebo first. Half of the participants receiving ketamine first met treatment response criteria at 1-week post-infusion. There were significant carryover effects suggesting that ketamine’s effects on OCD symptoms last longer than previously reported. Abstract Serotonin reuptake inhibitors (SRIs), the first-line...
- [Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion.](https://avyia.com/transient-resolution-of-treatment-resistant-posttraumatic-stress-disorder-following-ketamine-infusion/): D’Andrea, D., &amp; Sewesll, R. A. (2013). Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion. Biological Psychiatry, 74(9), e13–e14.  Highlights: An N-methyl-D-aspartate (NMDA) receptor antagonist with μ-opioid receptor effects, ketamine causes depression remission in most clinical trials attracting interest as a rapid-acting antidepressant We describe a case in which ketamine was given for treatment-resistant depression, but that caused serendipitous resolution of posttraumatic stress disorder (PTSD) symptoms.
- [Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.](https://avyia.com/antidepressant-efficacy-of-ketamine-in-treatment-resistant-major-depression-a-two-site-randomized-controlled-trial/): Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392. PMID: 23982301; PMCID: PMC3992936. Highlights: Ketamine showed rapid antidepressant effects with a single IV infusion of ketamine for patients with severe and chronic forms of depression. Compared to the placebo-controlled group using midazolam, the ketamine treatment group showed a better antidepressant response than placebo. 64% response rate was seen in the ketamine group vs. 28% with...
- [Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression.](https://avyia.com/rapid-and-longer-term-antidepressant-effects-of-repeated-ketamine-infusions-in-treatment-resistant-major-depression/): Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J. Akiki, Alok Madan, Leonardo Vando, Kristin Arden, Jack Swain, Madeline Klotz, Casey Paleos, At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial, Journal of Affective Disorders, Volume 314, 2022, Pages 59-67, SSN 0165-0327. Highlights: In this article, there were 24 patients treated with six IV infusions of ketamine (.5mg/kg) over 12 days. Participants with TRD (n=24) underwent a washout of antidepressant medication followed by a series of up to six intravenous (IV) infusions of ketamine...
- [At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-labeled effectiveness trial.](https://avyia.com/at-home-sublingual-ketamine-telehealth-is-a-safe-and-effective-treatment-for-moderate-to-severe-anxiety-and-depression-findings-from-a-large-prospective-open-labeled-effectiveness-trial/): Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J. Akiki, Alok Madan, Leonardo Vando, Kristin Arden, Jack Swain, Madeline Klotz, Casey Paleos, At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial, Journal of Affective Disorders, Volume 314, 2022, Pages 59-67, SSN 0165-0327. Highlights: Large, real-world data for an approach to delivering at-home ketamine-assisted therapy to ensure safety and increase access Influence of side effects and degree of dissociation for this treatment were determined for subpopulations Novel use of unsupervised machine learning to more fully...

## Pages

- [Intramuscular](https://avyia.com/intramuscular/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;column_reverse&#8221; bg_color=&#8221;#adcce9&#8243; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;5%&#8221; bottom_padding=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;right&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;iv_ketamine_s1&#8243; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;50px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; centered_text=&#8221;true&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;7/12&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#000000&#8243; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;Intramuscular (IM) ketamine&#8221; text_direction=&#8221;default&#8221; font_size=&#8221;4.5vw&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;10vw&#8221; font_size_phone=&#8221;12vw&#8221;][/split_line_heading][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]AVYIA’s recommended therapy for mental health illnesses.[/vc_column_text][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221;...
- [Tirzepatide](https://avyia.com/tirzepatide/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;column_reverse&#8221; bg_color=&#8221;#9481ad&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;5%&#8221; bottom_padding=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;right&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;iv_ketamine_s1&#8243; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;50px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; centered_text=&#8221;true&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/2&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;IV KETAMINE&#8221; text_direction=&#8221;default&#8221; font_size=&#8221;5vw&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;10vw&#8221; font_size_phone=&#8221;12vw&#8221;][/split_line_heading][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]AVYIA’s recommended therapy for mental health illnesses.[/vc_column_text][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243;...
- [Semaglutide](https://avyia.com/semaglutide/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;column_reverse&#8221; bg_color=&#8221;#9481ad&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;5%&#8221; bottom_padding=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;right&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;iv_ketamine_s1&#8243; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;50px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; centered_text=&#8221;true&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/2&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;IV KETAMINE&#8221; text_direction=&#8221;default&#8221; font_size=&#8221;5vw&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;10vw&#8221; font_size_phone=&#8221;12vw&#8221;][/split_line_heading][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]AVYIA’s recommended therapy for mental health illnesses.[/vc_column_text][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243;...
- [Microdosing Ketamine](https://avyia.com/microdosing-ketamine/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;column_reverse&#8221; bg_color=&#8221;#adcce9&#8243; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;5%&#8221; bottom_padding=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;right&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;iv_ketamine_s1&#8243; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;50px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; centered_text=&#8221;true&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;7/12&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#000000&#8243; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;Microdosing Ketamine&#8221; text_direction=&#8221;default&#8221; font_size=&#8221;5vw&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;10vw&#8221; font_size_phone=&#8221;12vw&#8221;][/split_line_heading][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]AVYIA’s recommended therapy for mental health illnesses.[/vc_column_text][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243;...
- [Nasal Ketamine](https://avyia.com/nasal-ketamine/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;column_reverse&#8221; bg_color=&#8221;#adcce9&#8243; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;5%&#8221; bottom_padding=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;right&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;iv_ketamine_s1&#8243; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;50px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; centered_text=&#8221;true&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;7/12&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#000000&#8243; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;NASAL KETAMINE&#8221; text_direction=&#8221;default&#8221; font_size=&#8221;5vw&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;10vw&#8221; font_size_phone=&#8221;12vw&#8221;][/split_line_heading][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]AVYIA’s recommended therapy for mental health illnesses.[/vc_column_text][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243;...
- [IV Ketamine](https://avyia.com/iv-ketamine/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;column_reverse&#8221; bg_color=&#8221;#adcce9&#8243; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;5%&#8221; bottom_padding=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;right&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;iv_ketamine_s1&#8243; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;50px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; centered_text=&#8221;true&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;7/12&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#000000&#8243; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;IV KETAMINE&#8221; text_direction=&#8221;default&#8221; font_size=&#8221;5vw&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;10vw&#8221; font_size_phone=&#8221;12vw&#8221;][/split_line_heading][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]AVYIA’s recommended therapy for mental health illnesses.[/vc_column_text][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243;...
- [Use of Website](https://avyia.com/use-of-website/): Use of Website AVYIA reserves the right to modify this agreement at any time, with any changes becoming effective immediately upon posting. By accessing and using this website, you agree to abide by these terms and conditions: Medical Disclaimer If you believe you are experiencing a medical emergency, including any suicidal or self-harm thoughts, call your doctor or 911 immediately. Do not rely on electronic communications or communication through this website for immediate, urgent medical needs. This website is not designed to facilitate medical emergencies. Health Content This website does not provide medical advice. Certain information on the site is...
- [HIPAA Privacy Policy](https://avyia.com/hipaa-privacy-policy/): HIPAA Privacy Policy At AVYIA, we prioritize the privacy and security of our users’ personal information, especially when it concerns health-related information. This Privacy Disclaimer outlines our practices regarding the collection, use, and disclosure of personal and health information when you use our medical website, in compliance with the Health Insurance Portability and Accountability Act (HIPAA). By accessing and using our website, you agree to the terms outlined in this Privacy Disclaimer. HIPAA Compliance: As a provider involved in the transmission and maintenance of Protected Health Information (PHI), we adhere strictly to the privacy and security rules set forth by...
- [Ketamine comparison page](https://avyia.com/ketamine-comparison-page/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;6%&#8221; bottom_padding=&#8221;4%&#8221; top_padding_tablet=&#8221;14%&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.8&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; shape_type=&#8221;&#8221; gradient_type=&#8221;default&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;20px&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;default&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; right_padding_phone=&#8221;0&#8243; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h2&#8243; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221; link_target=&#8221;_self&#8221; text_content=&#8221;Ketamine comparison&#8221; font_size=&#8221;6vw&#8221; text_direction=&#8221;default&#8221; font_line_height=&#8221;1&#8243; font_size_tablet=&#8221;7vw&#8221;][/split_line_heading][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row type=&#8221;in_container&#8221;...
- [Refund and Returns Policy](https://avyia.com/refund_returns/): AVYIA Funds &amp; Return Policy At AVYIA, we are committed to providing high-quality, personalized care through our ketamine and wellness programs. To ensure transparency and clarity, please review our funds and return policy carefully. Prescription Medications – No Refunds Due to federal regulations and safety protocols, AVYIA cannot offer refunds for prescription medications once they have been ordered or dispensed. This includes oral microdosing ketamine tablets, GLP-1 weight loss medications and other compounded prescriptions, which are often filled in 3- to 6-month quantities to support continuity of care. This applies to monthly subscription and multiple-months pre-pay programs.  Once an order...
- [Suicidal Ideation](https://avyia.com/suicidal-ideation/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_image=&#8221;7014&#8243; bg_position=&#8221;left top&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221;...
- [OCD](https://avyia.com/ocd/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_image=&#8221;7012&#8243; bg_position=&#8221;left top&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221;...
- [Migraines](https://avyia.com/migraine/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_image=&#8221;7019&#8243; bg_position=&#8221;left top&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221;...
- [PTSD](https://avyia.com/ptsd/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; video_bg=&#8221;use_video&#8221; enable_video_color_overlay=&#8221;true&#8221; video_mp4=&#8221;https://avyia.com/wp-content/uploads/2025/02/PTSD.mp4&#8243; background_video_loading=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221;...
- [Bipolar](https://avyia.com/bipolar/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_image=&#8221;7292&#8243; bg_position=&#8221;left top&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221;...
- [Anxiety](https://avyia.com/anxiety/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_image=&#8221;7015&#8243; bg_position=&#8221;left top&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; advanced_gradient_angle=&#8221;213&#8243; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#ffffff&#8221; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221;...
- [Depression](https://avyia.com/depression/): [vc_row type=&#8221;full_width_background&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; video_bg=&#8221;use_video&#8221; video_mp4=&#8221;/wp-content/uploads/2025/02/Depression.mp4&#8243; background_video_loading=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; enable_gradient=&#8221;true&#8221; color_overlay_2=&#8221;#ededed&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;15%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;0&#8243; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#000000&#8243; font_size_max=&#8221;108px&#8221; line_reveal_by_space_text_effect=&#8221;letter-reveal-bottom&#8221; stagger_animation=&#8221;true&#8221; content_alignment=&#8221;default&#8221; mobile_content_alignment=&#8221;inherit&#8221;...
- [Ketamine](https://avyia.com/ketamine/): [vc_row type=&#8221;full_width_content&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_image=&#8221;8228&#8243; bg_position=&#8221;center center&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; bottom_padding=&#8221;1%&#8221; left_padding_desktop=&#8221;5%&#8221; right_padding_desktop=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; color_overlay_2=&#8221;#ffffff&#8221; advanced_gradient_angle=&#8221;355&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;top_to_bottom&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner right_padding_desktop=&#8221;50%&#8221; right_padding_tablet=&#8221;50%&#8221; right_padding_phone=&#8221;15%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][split_line_heading animation_type=&#8221;line-reveal-by-space&#8221; font_style=&#8221;h1&#8243; text_color=&#8221;#000000&#8243; font_size_max=&#8221;108px&#8221;...
- [Shop](https://avyia.com/shop/)
- [Home](https://avyia.com/): [vc_row type=&#8221;full_width_content&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bg_color=&#8221;#f8f8f8&#8243; bg_image=&#8221;10265&#8243; bg_image_phone=&#8221;10234&#8243; bg_position=&#8221;center center&#8221; background_image_loading=&#8221;default&#8221; bg_repeat=&#8221;no-repeat&#8221; full_height=&#8221;yes&#8221; columns_placement=&#8221;bottom&#8221; scene_position=&#8221;center&#8221; bottom_padding=&#8221;1%&#8221; left_padding_desktop=&#8221;5%&#8221; right_padding_desktop=&#8221;5%&#8221; text_color=&#8221;light&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;custom&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; class=&#8221;hero_section&#8221; enable_gradient=&#8221;true&#8221; color_overlay=&#8221;#ededed&#8221; color_overlay_2=&#8221;rgba(237,237,237,0.01)&#8221; advanced_gradient_angle=&#8221;180&#8243; overlay_strength=&#8221;0.95&#8243; gradient_direction=&#8221;left_b_to_right_t&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;zoom-out&#8221; mobile_disable_bg_image_animation=&#8221;true&#8221; parallax_bg=&#8221;true&#8221; parallax_bg_speed=&#8221;medium_fast&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;curve&#8221;][vc_column bottom_padding_desktop=&#8221;40px&#8221; bottom_padding_phone=&#8221;40px&#8221; bottom_margin=&#8221;0%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221; column_padding_type=&#8221;advanced&#8221; gradient_type=&#8221;default&#8221;][vc_row_inner equal_height=&#8221;yes&#8221; content_placement=&#8221;bottom&#8221; column_margin=&#8221;10px&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; bottom_padding=&#8221;5%&#8221; right_padding_phone=&#8221;30&#8243; text_align=&#8221;left&#8221; row_position=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; pointer_events=&#8221;all&#8221;][vc_column_inner bottom_padding_desktop=&#8221;0%&#8221; right_padding_desktop=&#8221;50%&#8221; right_padding_tablet=&#8221;40%&#8221; right_padding_phone=&#8221;40&#8243; bottom_margin=&#8221;0%&#8221; bottom_margin_phone=&#8221;0%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;left&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; overflow=&#8221;visible&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;2/3&#8243;...
- [Blog](https://avyia.com/blog/): [vc_row type=&#8221;full_width_content&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; shape_type=&#8221;&#8221; gradient_type=&#8221;default&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221;][recent_posts style=&#8221;multiple_large_featured&#8221; large_featured_padding=&#8221;14%&#8221; mlf_navigation_location=&#8221;side&#8221; button_color=&#8221;Accent-Color&#8221; button_arrow_style=&#8221;default&#8221; load_in_animation=&#8221;none&#8221; large_featured_content_max_width=&#8221;default&#8221; bg_overlay=&#8221;solid_color&#8221; large_featured_heading_tag=&#8221;h2&#8243; category=&#8221;all&#8221; multiple_large_featured_num=&#8221;3&#8243; order=&#8221;DESC&#8221; orderby=&#8221;date&#8221; auto_rotate=&#8221;8000&#8243; image_loading=&#8221;default&#8221;][/vc_column][/vc_row][vc_row type=&#8221;in_container&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; top_padding=&#8221;9%&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221; gradient_type=&#8221;default&#8221; shape_type=&#8221;&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; top_margin=&#8221;-5%&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221;...


[comment]: # (Generated by Hostinger Tools Plugin)